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Abstract
Background
United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs
(bDMARDS) for rheumatoid arthritis (RA) require patients to have active disease (Disease
Activity Score [DAS28] >5.1) and have failed�2 previous conventional synthetic DMARDs
(csDMARD). Patients with moderate disease activity (MDA) do not meet these criteria, yet
often have poor outcomes. This study aimed to identify trajectory groups of disability scores
over three years in RA patients with MDA.
Methods
The study included biologic-naïve patients receiving csDMARDs only with MDA (3.2
<DAS28� 5.1) when recruited to the control cohort of the British Society for Rheumatology
Biologics Register–RA (BSRBR-RA). Disability scores, measured using the Health Assess-
ment Questionnaire (HAQ), were recorded every six months for three years. Trajectories of
HAQ scores over follow-up were assessed using latent class growth models (LCGMs).
Baseline age, gender, DAS28, symptom duration, rheumatoid factor status, number of prior
csDMARDs and co-morbidities were assessed as potential predictors of group
membership.
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Results
In total, 1274 patients were included (mean age: 61 years (standard deviation: 12), 71.4%
women). The best fitting model included seven HAQ trajectories. These trajectories were
horizontal over follow-up and were related to baseline HAQ: very-low (6.8%, baseline (BL)
HAQ: 0.22), low (11.5%, BL HAQ: 0.41), low-moderate (17.0%, BL HAQ: 0.93), moderate
(13.4%, BL HAQ: 1.09), high-moderate (19.5%, BL HAQ: 1.61), severe (23.2%, BL HAQ:
1.98) and very-severe (8.6%, BL HAQ: 2.54). Higher DAS28, older age, female gender, lon-
ger disease duration and more co-morbidities were independently associated with higher
HAQ trajectory group.
Conclusion
There is substantial heterogeneity in baseline HAQ scores in this population, and the trajec-
tories of HAQ scores after baseline are, on average, relatively flat. As bDMARD therapy has
been shown to improve HAQ scores, patients with MDA but high HAQ scores may benefit
from a more aggressive approach to therapy.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune condition, which is associated with
inflammation of synovial joints and may result in increased disability and reduced quality of
life [1]. Over the past two decades, the treatment of RA has been revolutionised by the intro-
duction of biologic disease modifying anti-rheumatic drugs (bDMARDs) [2]. These drugs
have been demonstrated to be effective at lowering disease activity, improving functional abil-
ity, and reducing mortality [3,4]. However, the strict United Kingdom (UK) National Institute
for Health and Care Excellence (NICE) guidelines require patients to have high disease activity
(Disease Activity Score 28 [DAS28] >5.1), and have failed two conventional synthetic
DMARDs (csDMARDs) [5], before starting a bDMARD.
Patients with moderate disease activity (MDA; 3.2< DAS28� 5.1) and who thus fail to
reach the criteria for bDMARD treatment in the UK, have poor long-term outcomes [6–8].
For example, patients from the French Etude et Suivi des Polyarthrites Indifférenciées Récentes
(ESPOIR) cohort assessed between the six and 12 month visits who had persistent MDA had
two-fold increased odds of radiographic damage and higher disability scores (measured using
the Heath Assessment Questionnaire (HAQ)) at three years compared with patients in remis-
sion [6]. Similarly, patients from the UK Early Rheumatoid Arthritis Network (ERAN) cohort
with DAS28 <3.2 at year one had seven-fold increased odds of having low DAS28 and three-
fold increased odds of having low HAQ scores at year two compared with patients with MDA
at year one [7]. In another UK study, almost a quarter of patients (21.4%) with persistent
MDA recruited to the Yorkshire Early Arthritis Register had increases in HAQ score above the
minimum clinically important difference over a six month period [8]. Furthermore, research
has shown that the administration of bDMARDs to patients with MDA leads to improved out-
comes compared with methotrexate alone [9,10].
Previous studies assessing patients with MDA have analysed the cohorts as single homoge-
nous groups. However, as the DAS28 definition for MDA is wide (1.9 units) and as the DAS28
is made up of 4 separate components, this group is likely to be heterogeneous. The total MDA
population may be made up of subgroups characterised by distinct trajectories of long-term
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outcome such as functional ability. Therefore, the aim of this study was to determine whether
there are multiple trajectories of HAQ scores over three years in patients with MDA at base-
line, and to identify predictors of group membership where they exist. This research will allow
the identification of groups of patients with MDA who are likely to have worse long-term out-
comes and who may benefit from more aggressive therapy.
Patients and methods
Study population
The British Society for Rheumatology Biologics Register for RA (BSRBR-RA) is an ongoing
national, observational cohort study of outcomes among patients receiving bDMARDs for RA
[11]. In order to place any observed adverse events into context and to understand the risks of
bDMARDs compared to csDMARDs, a cohort of 3800 patients with RA and at least MDA
(but not eligible for biologic therapy), was also recruited in parallel between 2002 and 2009
[12]. The BSRBR-RA csDMARD group included patients with early RA starting csDMARDs
for the first time and patients with more longstanding RA who had received more than one
csDMARD prior to recruitment. Patients from the BSRBR-RA csDMARD cohort were
included in this analysis if they had MDA at study registration (baseline) (3.2< DAS28� 5.1)
and had HAQ recorded at baseline (N = 1274). Ethical approval was granted by the North
West Multicentre Research Ethics Committee in December 2000 (MREC 00/8/53) and
patients gave their written informed consent to participate and for their data to be used in fur-
ther analyses investigating the long-term outcomes of RA.
Data collection
At study registration, data were extracted from patients and from medical records and
included age, gender, symptom duration, baseline HAQ score, baseline DAS28, rheumatoid
factor (RF) status, information about prior csDMARD use and co-morbidities, which were
selected from a pre-determined list of conditions. Outcome data, including changes in treat-
ment, disease activity, HAQ scores and adverse events were collected every six months for
three years.
Statistical analysis
Descriptive statistics were used to summarise the baseline characteristics of the patients. Dis-
tinct trajectories of functional disability (HAQ, bounded between 0 and 3) over time were
identified using latent class growth models (LCGMs) [13]. The model included two parts: (a) a
censored normal based trajectory model using time polynomials as covariates, such as linear,
quadratic and cubic terms of years since registration; (b) a multinomial logistic regression
model for class membership using baseline characteristics as predictors. Predictors assessed
were: baseline age, gender, symptom duration, DAS28, RF positivity, number of prior
csDMARDs and number of co-morbidities (composite variable generated from the presence
of high blood pressure, ischaemic heart disease, stroke, lung disease, renal disease, liver disease,
diabetes mellitus or depression).
Patients with missing baseline HAQ data were excluded, but patients with some missing
follow-up HAQ scores were included and contributed data to other time-points within the
model. The LCGM analysis was performed using the Stata plugin traj [14]. In order to deter-
mine the number of latent classes (trajectory groups), initially a single class of LCGM was fitted
which is equivalent to a simple linear regression model and then models allowing up to nine
latent groups were estimated. Both Akaike’s information criterion (AIC) and (adjusted)
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Bayesian information criterion (adjusted BIC) were used to select the optimum model, with
values closest to zero indicating better model fit. Since the second part of the model employs
multinomial logistic regression, we imposed a further stipulation that no latent class could
contain less than 5% of the total sample (n<64) for reasons of power and precision. After
determining the best-fitting model, we then examined the association of these groups with
demographic and clinical baseline characteristics using multinomial logistic regression analy-
sis. Cox proportional hazards models were then used to assess the association between trajec-
tory group membership and subsequent death and starting a biologic over the first three years
of follow-up. Patients were censored after three years.
Missing data on baseline predictors were low (14 missing data-points out of 8918 [0.2%]).
Multiple imputation using iterative chained equations was used to account for these missing
data, with 10 imputed datasets created. Imputed variables were only used as predictors in the
multinomial logistic regression model. A sensitivity analysis was conducted, limiting the analy-
sis to patients with�2 years symptom duration at baseline (N = 395, 31%). All analyses were
performed using Stata 13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Sta-
tion, TX: StataCorp LP).
Results
A total of 1274 csDMARD patients had MDA at study registration and completed baseline
HAQ and were therefore included. These patients had a mean age (standard deviation) at base-
line of 61.1 (12.3) years and 910 (71.4%) were women (Table 1). Of those included in the analy-
sis, 63 (5.0%) patients died during follow-up and 49 (3.9%) patients switched to bDMARD
therapy within the first three years following registration.
The median number of HAQ scores per patient was 6 (IQR 3, 7) and the median HAQ
score at each assessment over the course of three years was 1.38 (IQR 0.63, 1.88). At the sample
level, the progression of HAQ score was stable over time (Fig 1A). However, sample level sta-
tistics, such as the median, can mask the between-individual variability in HAQ score over
time as shown by the trajectories of 16 randomly selected patients (Fig 1B). Therefore, LCGMs
were fitted, allowing for several distinct HAQ trajectories over time.
Table 1. Baseline characteristics of the analysis cohort, mean (standard deviation) displayed unless otherwise stated.
% missing BSRBR-RA, N = 1274 Min Max
Age at registration, years 0 61.1 (12.3) 18 90
Gender, N (%) female 0 910 (71.4)
Symptom duration, years 1.0 10.3 (10.6) 0 65
HAQ score 0 1.36 (0.75) 0 3
DAS28 score 0 4.34 (0.50) 3.20 5.10
Rheumatoid factor, N (%) positive 0.08 755 (59.3)
Number of prior DMARDs 0 2.4 (1.7) 0 10
Co-morbidity, n (%) 0
None 516 (40.5)
1 co-morbidity 447 (35.1)
2 co-morbidities 216 (17.0)
� 3 co-morbidities 95 (7.5)
DAS28 = Disease Activity Score (28), DMARD = disease modifying anti-rheumatic drug, HAQ = health assessment questionnaire, N = number
Co-morbidities included: high blood pressure, ischaemic heart disease, stroke, lung disease, renal disease, liver disease, diabetes mellitus, depression
https://doi.org/10.1371/journal.pone.0215999.t001
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Latent class growth models
Trajectory groups. The fit of models with one to nine latent classes were evaluated. A
model including seven latent classes was selected as having the best (i.e. most parsimonious) fit
to the data. There was heterogeneity in the HAQ scores of patients with MDA at baseline (Fig
2). The HAQ trajectories of patients from baseline were horizontal and were associated with
the HAQ score of each trajectory at baseline. The groups were labelled as follows, based on
baseline HAQ: very-low (Group 1, 6.8%, mean baseline (BL) HAQ: 0.22), low (Group 2,
11.5%, BL HAQ: 0.41), low-moderate (Group 3, 17.0%, BL HAQ: 0.93), moderate (Group 4,
13.4%, BL HAQ: 1.09), high-moderate (Group 5, 19.5%, BL HAQ: 1.61), severe (Group 6,
23.2%, BL HAQ: 1.98) and very-severe (Group 7, 8.6%, BL HAQ: 2.54).
Fig 1. Box plot of HAQ scores distribution and HAQ trajectories for 16 random subjects.
https://doi.org/10.1371/journal.pone.0215999.g001
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Trajectory group characteristics. The baseline characteristics of the seven trajectory
groups are summarized in Table 2. There were clear correlations between increasing trajectory
group (i.e. worsening of HAQ scores) and older age, higher proportion of females, longer dis-
ease duration, worse baseline HAQ score, worse baseline DAS28, higher proportion of RF
+ patients, more prior csDMARDs used and more co-morbidities. When assessing baseline
predictors of HAQ score using multinomial logistic regression, the strongest independent pre-
dictor of group membership was DAS28 (relative risk ratio per unit increase in baseline
DAS28 [95% CI]: trajectory 1 = 1 [reference category], trajectory 2 = 0.94 [0.55, 1.58]; trajec-
tory 3 = 1.71 [1.04, 2.82], trajectory 4 = 2.12 [1.25, 3.60], trajectory 5 = 2.31 [1.40, 3.83], trajec-
tory 6 = 2.57 [1.56, 4.25], trajectory 7 = 3.14 [1.70, 5.81]). Other baseline factors that showed
Fig 2. HAQ disability trajectories for the 7 latent classes.
https://doi.org/10.1371/journal.pone.0215999.g002
Table 2. Baseline characteristics of the analysis cohort by trajectory group (n = 1274), mean (standard deviation) displayed unless otherwise stated.
Trajectory Group 1 2 3 4 5 6 7
Very-Low Low Low-moderate Moderate High-moderate Severe Very-severe
Number of patients, n (%) 87 (6.8) 146 (11.5) 217 (17.0) 171 (13.4) 248 (19.5) 296 (23.2) 109 (8.6)
Age at registration, years 57.5 (12.3) 56.9 (11.7) 57.4 (12.7) 63.0 (11.7) 62.1 (12.0) 63.1 (12.1) 65.8 (10.6)
Gender, n (%) female 55 (63.2) 91 (62.3) 160 (73.7) 112 (65.5) 178 (71.8) 220 (74.3) 94 (86.2)
Symptom duration, years 6.0 (7.3) 7.0 (8.2) 7.8 (8.8) 9.6 (10.4) 10.8 (10.9) 12.1 (10.5) 18.7 (13.4)
HAQ 0.22 (0.33) 0.41 (0.33) 0.93 (0.37) 1.09 (0.36) 1.61 (0.31) 1.98 (0.31) 2.54 (0.23)
DAS28 4.21 (0.52) 4.17 (0.52) 4.33 (0.51) 4.36 (0.47) 4.38 (0.50) 4.40 (0.48) 4.44 (0.44)
RF+, n (%) 51 (58.6) 80 (54.8) 118 (54.4) 97 (56.7) 147 (59.3) 186 (63.1) 76 (69.7)
Prior DMARDs 1.7 (1.4) 2.0 (1.5) 2.0 (1.6) 2.2 (1.7) 2.4 (1.5) 2.8 (1.7) 3.2 (1.7)
No co-morbidity 55 (63.2) 79 (54.1) 124 (57.1) 66 (38.6) 86 (34.7) 74 (25.0) 32 (29.4)
1 co-morbidity 20 (23.0) 41 (28.1) 70 (32.3) 68 (39.8) 96 (38.7) 112 (37.8) 40 (36.7)
2 co-morbidities 11 (12.6) 20 (13.7) 14 (6.5) 27 (15.8) 46 (18.6) 75 (25.3) 23 (21.1)
�3 co-morbidities 1 (1.2) 6 (4.1) 9 (4.2) 10 (5.9) 20 (8.1) 35 (11.8) 14 (12.8)
DAS28 = Disease Activity Score (28), DMARD = disease modifying anti-rheumatic drug, HAQ = Health Assessment Questionnaire, N = number, RF = rheumatoid
factor
https://doi.org/10.1371/journal.pone.0215999.t002
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an independent association with trajectory group were age, gender, disease duration, number
of prior csDMARDs and number of co-morbidities, whereas positive RF was not associated
with higher trajectory group (Table 3). There was no significant relationship between increas-
ing HAQ trajectory group and death during follow-up or starting a biologic (see S1 Table).
The sensitivity analysis produced similar results to the main analyses.
Discussion
This study aimed to describe the heterogeneity in disability over three years of RA patients
with baseline MDA by identifying distinct trajectories of HAQ score. There was significant
heterogeneity in HAQ scores at baseline within this patient group, despite all having moderate
disease activity. A seven trajectory group model fitted the follow-up data best, but each of these
trajectories was characterised by relatively constant HAQ scores, associated with baseline
HAQ. This is in spite of csDMARD therapy, indicating the potential for more aggressive treat-
ment strategies in patients with MDA and high HAQ scores.
Currently, the treatment decision to start a patient with RA on a bDMARD is driven solely
by DAS28. To select patients early who could potentially benefit from treatment with a bio-
logic, it may be important to consider DAS28 and HAQ score together, given the results of this
paper indicating significant heterogeneity in HAQ scores in a cohort of patients with MDA.
The NICE cost-effectiveness model for biologics explicitly included variability in baseline
HAQ score into their models [5], and a working group aiming to achieve consensus in deci-
sion models for biologics in RA concluded HAQ should be included in economic models [15],
indicating the potential importance of thinking about HAQ and DAS28 when selecting
patients to start biologic therapy.
LCGMs have previously been applied to the HAQ scores of patients with inflammatory
arthritis included in two UK inception cohorts (the Early Rheumatoid Arthritis Study [ERAS],
and the Norfolk Arthritis Register [NOAR]) [16,17]. These analyses reported four HAQ trajec-
tory groups, as opposed to the seven reported in this analysis. This could be due to differences
in entry criteria for the different studies (e.g. this analysis: prevalent cases with MDA; ERAS,
NOAR analyses: inception cases with any disease activity) or due to differences in follow-up
length (this study: 3 years; ERAS: 10 & 15 years; NOAR: 15 years) or differences in the criteria
used to determine the optimal number of trajectory classes (this study: AIC and BIC; ERAS:
Table 3. Baseline independent predictors of trajectory group membership, results are relative risk ratios (95% confidence intervals) with trajectory group 1 as the
reference category.
Trajectory Group 1 2 3 4 5 6 7
Very-Low Low Low-moderate Moderate High-moderate Severe Very-severe
Age at registration 1(ref) 0.99 (0.97, 1.01) 1.00 (0.98, 1.02) 1.03 (1.00, 1.05) 1.02 (1.00, 1.04) 1.02 (1.00, 1.04) 1.04 (1.01, 1.07)
Female vs male 1(ref) 0.93(0.53, 1.62) 1.52(0.89, 2.62) 1.10(0.63, 1.92) 1.45(0.85, 2.49) 1.71(1.00, 2.94) 3.84(1.83, 8.03)
Symptom duration, years 1(ref) 1.01(0.97, 1.05) 1.02(0.99, 1.06) 1.03(0.99, 1.07) 1.04(1.00, 1.08) 1.04(1.01, 1.08) 1.08(1.04, 1.12)
DAS28 1(ref) 0.94(0.55, 1.58) 1.71(1.04, 2.82) 2.12(1.25, 3.60) 2.31(1.40, 3.83) 2.57(1.56, 4.25) 3.14(1.70, 5.81)
RF+ vs RF- 1(ref) 0.80(0.46, 1.33) 0.76(0.45, 1.27) 0.78(0.45, 1.33) 0.84(0.50, 1.41) 0.94(0.56, 1.58) 1.14(0.60, 2.13)
Prior DMARDs 1(ref) 1.24(0.97, 1.57) 1.16(0.92, 1.46) 1.30(1.02, 1.64) 1.35(1.06, 1.68) 1.54(1.24, 1.92) 1.57(1.23, 1.99)
1 co-morbidity vs no co-morbidity 1(ref) 1.47(0.77, 2.80) 1.57(0.86, 2.87) 2.54(1.36, 4.77) 2.88(1.57, 5.28) 3.99(2.16, 7.36) 3.28(1.57, 6.82)
2 co-morbidities vs no co-morbidity 1(ref) 1.33(0.58, 3.04) 0.59(0.25, 1.40) 1.79(0.80, 4.01) 2.49(1.16, 5.34) 4.76(2.23, 10.13) 3.29(1.34, 8.04)
�3 co-morbidities vs no co-morbidity 1(ref) 4.53(0.52, 39.30) 4.54(0.55, 37.37) 7.00(0.85, 57.60) 11.98(1.53, 94.01) 24.16(3.12, 187.1) 21.58 (2.58, 180.2)
DAS28 = Disease Activity Score (28), DMARD = Disease modifying Anti-Rheumatoid Drug, N = number, RF = rheumatoid factor
https://doi.org/10.1371/journal.pone.0215999.t003
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Likelihood ratio test; NOAR: validation of ERAS groups). The analyses of ERAS and NOAR
also assessed predictors of group membership, reporting that baseline older age, female sex,
longer symptom duration and higher DAS28 were associated with higher HAQ trajectory
group membership, in line with the results from this analysis [17]. However, while we found
no association with mortality, in ERAS where mortality was considered, individuals in a high
stable and moderate increasing trajectory group were observed to be associated with increased
mortality risk [16]. However, there were relatively few deaths across the seven trajectories in
the current analysis, meaning that the survival analysis in this study may be underpowered.
More comorbidity was also associated with higher HAQ trajectory group in the current
analysis. Patients with conditions such as fibromyalgia and other musculoskeletal conditions
alongside their RA are likely to be over-represented in the higher HAQ trajectories as well as
higher disease activity groups [18,19]. However, as data on fibromyalgia were not collected
consistently in the BSRBR-RA, we cannot test this.
The current study has a number of strengths. The large sample size and the multiple
repeated assessments allow the construction of robust LCGMs. A wide range of demographic
and clinical predictors were available to be screened as predictors of group membership.
Patients came from 28 different centres across the UK, meaning the results can be generalised
to patients across the country. A weakness of this research is that there were some missing
baseline HAQ scores for some patients, and hence these patients were not included in the anal-
ysis. However, the number of patients excluded was low (N = 137) and the baseline character-
istics of these patients did not differ from patients with measured baseline HAQ score and
therefore any bias due to complete-case analysis is likely to be minimal. Furthermore, HAQ
score is a subjective measure of functional disability and there were no objective measures of
function within the BSRBR to corroborate the heterogeneity observed in the HAQ scores. A
further weakness is that no other disease activity measures were collected within the
BSRBR-RA, (e.g. the Clinical Disease Activity Index or the Simplified Disease Activity Index)
meaning we could not assess the heterogeneity of HAQ scores in a cohort of moderate disease
activity patients defined using a disease activity measure other than the DAS28.
In conclusion, this analysis has identified seven distinct HAQ trajectory groups in patients
who have MDA at baseline, indicating that this is a heterogeneous population with a range of
potential long-term outcomes. These trajectories were relatively stable over time, despite
csDMARD therapy. Biologic therapies have been shown to improve physical function in RA
patients with MDA [9,10,20]. This study indicates that some patients with RA and MDA have
high levels of disability and these patients are likely to continue having high disability over sub-
sequent years. These patients should be identified and may benefit from more aggressive ther-
apy, such as biologic therapy, despite their moderate disease activity.
BSRBR-RA Control Centre Consortium
The BSRBR-RA Control Centre Consortium recruited a cohort of patients receiving conven-
tional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) between 2002 and
2009. This Consortium consists of the following institutions (all in the UK): Antrim Area Hos-
pital, Antrim (Dr Nicola Maiden), Cannock Chase Hospital, Cannock Chase (Dr Tom Price),
Christchurch Hospital, Christchurch (Dr Neil Hopkinson), Royal Derby Hospital, Derby (Dr
Sheila O’Reilly), Dewsbury and District Hospital, Dewsbury (Dr Lesley Hordon), Freeman
Hospital, Newcastle-upon-Tyne (Dr Ian Griffiths), Gartnavel General Hospital, Glasgow (Dr
Duncan Porter), Glasgow Royal Infirmary, Glasgow (Prof Hilary Capell), Haywood Hospital,
Stoke-on-Trent (Dr Andy Hassell), Hope Hospital, Salford (Dr Romela Benitha), King’s Col-
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